New 'Columbus strain' of coronavirus evolved in the US
The variant has three gene mutations that haven't previously been seen together.
Get the world’s most fascinating discoveries delivered straight to your inbox.
You are now subscribed
Your newsletter sign-up was successful
Want to add more newsletters?
Delivered Daily
Daily Newsletter
Sign up for the latest discoveries, groundbreaking research and fascinating breakthroughs that impact you and the wider world direct to your inbox.
Once a week
Life's Little Mysteries
Feed your curiosity with an exclusive mystery every week, solved with science and delivered direct to your inbox before it's seen anywhere else.
Once a week
How It Works
Sign up to our free science & technology newsletter for your weekly fix of fascinating articles, quick quizzes, amazing images, and more
Delivered daily
Space.com Newsletter
Breaking space news, the latest updates on rocket launches, skywatching events and more!
Once a month
Watch This Space
Sign up to our monthly entertainment newsletter to keep up with all our coverage of the latest sci-fi and space movies, tv shows, games and books.
Once a week
Night Sky This Week
Discover this week's must-see night sky events, moon phases, and stunning astrophotos. Sign up for our skywatching newsletter and explore the universe with us!
Join the club
Get full access to premium articles, exclusive features and a growing list of member rewards.
Two new COVID-19 variants have been found in Ohio, and they appear to have originated in the United States, researchers announced on Wednesday (Jan. 13).
One of these variants, dubbed the "Columbus strain," has three gene mutations that haven't previously been seen together in SARS-CoV-2, the virus that causes COVID-19, according to a statement from The Ohio State University Wexner Medical Center. These mutations occur in the so-called spike protein of the virus, which it uses to latch onto cells.
This strain quickly became the dominant coronavirus variant in Columbus, Ohio, over a three-week period from late December 2020 to early January, according to the researchers, who hope to post their findings soon on the pre-print database bioRxiv.
Related: Fast spreading U.K. variant: All your questions answered
"This new Columbus strain has the same genetic backbone as earlier cases we've studied, but these three mutations represent a significant evolution," study leader Dr. Dan Jones, vice chair of the division of molecular pathology at they Wexner Medical Center, said in the statement. "We know this shift didn't come from the U.K. or South African branches of the virus."
The Ohio researchers have been regularly sequencing the SARS-CoV-2 genome from patient samples since March 2020 to monitor the virus's evolution.
Like other coronavirus variants found around the world, including the U.K. variant, the mutations in the Columbus strain occur in the virus's "spike protein," which allows the virus to enter cells. It's possible these mutations make the virus more transmissible, the researchers said.
Get the world’s most fascinating discoveries delivered straight to your inbox.
But so far, there is no evidence that these mutations would impact the effectiveness of COVID-19 vaccines, according to the researchers.
"It's important that we don't overreact to this new variant until we obtain additional data," said Peter Mohler, a co-author of the study and chief scientific officer at the Wexner Medical Center
The second variant found by the Ohio researchers has a mutation dubbed 501Y that is identical to one seen in the U.K. variant. This mutation affects the receptor-binding domain, or part of the virus's spike protein that latches onto the ACE2 receptor in human cells; in lab-dish experiments, the mutated receptor-binding domain binds more tightly to the ACE2 receptor, past research found.
But the researchers believe the Ohio variant independently evolved that mutation from a strain already in the U.S. It was found in one patient from Ohio, so the researchers don't yet know how prevalent it is in the population overall.
A spokesperson for the Centers for Disease Control and Prevention told CNBC that the agency is reviewing the new research.
Originally published on Live Science.

Rachael is a Live Science contributor, and was a former channel editor and senior writer for Live Science between 2010 and 2022. She has a master's degree in journalism from New York University's Science, Health and Environmental Reporting Program. She also holds a B.S. in molecular biology and an M.S. in biology from the University of California, San Diego. Her work has appeared in Scienceline, The Washington Post and Scientific American.
